Comparator: ondansetron

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Chemotherapy-Induced Nausea and VomitingPost-Operative Nausea and Vomiting

Phase 1

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

TerminatedNCT00818259

Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting

Start: 2009-02-05End: 2014-01-20Updated: 2018-09-25

Phase 3

A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)

CompletedNCT00231777

Merck Sharp & Dohme LLCPost-Operative Nausea and Vomiting

Start: 2005-07-31End: 2005-11-30Updated: 2015-08-19

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

CompletedNCT00337727

Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting

Start: 2007-01-01End: 2008-11-19Updated: 2017-06-02

Related Papers

Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region

Current Medical Research and Opinion2014-06-0915 citations